Development of a Grp94 inhibitor

Citations Over TimeTop 10% of 2012 papers

Abstract

Heat shock protein 90 (Hsp90) represents a promising therapeutic target for the treatment of cancer and other diseases. Unfortunately, results from clinical trials have been disappointing as off-target effects and toxicities have been observed. These detriments may be a consequence of pan-Hsp90 inhibition, as all clinically evaluated Hsp90 inhibitors simultaneously disrupt all four human Hsp90 isoforms. Using a structure-based approach, we designed an inhibitor of Grp94, the ER-resident Hsp90. The effect manifested by compound 2 on several Grp94 and Hsp90α/β (cytosolic isoforms) clients were investigated. Compound 2 prevented intracellular trafficking of the Toll receptor, inhibited the secretion of IGF-II, affected the conformation of Grp94, and suppressed Drosophila larval growth, all Grp94-dependent processes. In contrast, compound 2 had no effect on cell viability or cytosolic Hsp90α/β client proteins at similar concentrations. The design, synthesis, and evaluation of 2 are described herein.

Related Papers

• → Selective Inhibition of the Hsp90α Isoform(2021)72 cited
• → GCUNC45 Is the First Hsp90 Co-chaperone to Show α/β Isoform Specificity(2008)44 cited
• → Identification of Isoform-Selective Ligands for the Middle Domain of Heat Shock Protein 90 (Hsp90)(2019)18 cited
• → Selective Inhibition of the Hsp90α Isoform(2021)1 cited
• → Rapid identification of metallothionein isoforms in liver cytosol fraction by capillary zone electrophoresis using EDTA(2000)10 cited